Signs and Symptoms

The signs and symptoms of amyloidosis depend on the location and size of the amyloid deposits.

AL may affect any tissue. Signs and symptoms may be vague and can include the following:

• Heart disease and irregular heart beat -- The heart is involved in about 50% of patients with AL.
• Stroke
• Kidney disorders, including kidney failure
• Gastrointestinal (GI) disorders, such as perforation (hole), bleeding, slow movement of matter through the GI tract, and blockage
• Enlarged liver
• Diminished function of the spleen
• Diminished function of the adrenal and other endocrine glands
• Skin conditions, such as growths, color changes, purpura (bleeding into the skin) around the eyes, and easy bruising
• Enlarged tongue, sometimes with swelling under the jaw, breathing difficulties, and sleep apnea
• Lung problems
• Swelling of the shoulder joints (may look like shoulder pads under the skin)
• Bleeding problems
• Fatigue
• Weight loss

Signs and symptoms of hereditary amyloidosis may include the following:

• Nervous system disorders
• Gastrointestinal conditions, such as diarrhea and weight loss
• Heart problems
• Carpal tunnel syndrome
• Kidney disease, though this is less common than in AL

Signs and symptoms of secondary amyloidosis may include the following:

• Kidney disease, which may lead to kidney failure; this is the cause of death in 40 - 60% of cases.
• Enlarged liver
• Enlarged spleen
• Heart problems -- this is rare, and less severe than in other forms of amyloidosis.

Most people who are diagnosed with AA have had their related inflammatory disease for a decade or more.

What Causes It?

No one knows what causes amyloidosis. There may be more than one cause. Hereditary amyloidosis results from genetic changes that cause the body to make abnormal proteins. Researchers think that as we get older, damage builds up in the body and triggers the disease. This kind of damage may come from the body's use of oxygen (oxidation) and from free radicals (harmful byproducts formed when cells use energy). Amyloid is also more likely to form in people who have immune system problems. Once amyloid deposits start, they seem to continue building up in the same locations. The heart, kidneys, nervous system, and GI tract are the most commonly affected.

Who's Most At Risk?

People with the following profile are at increased risk for developing amyloidosis:

• Men -- two thirds of people with AL are men.
• People over age 50 -- even in people with hereditary forms, doctors usually detect amyloid deposits severe enough to cause problems later in life.
• Disease affecting the antibody-producing plasma cells in the blood (such as multiple myeloma, malignant lymphoma, benign monoclonal gammopathy, or Waldenström's macroglobulinemia)
• Chronic infectious or inflammatory disease (such as rheumatoid arthritis, inflammatory bowel disease, familial Mediterranean fever, or ankylosing spondylitis)
• Long-term dialysis
• Inherited genetic changes that affect proteins in the body

What to Expect at Your Provider's Office

Your health care provider may suspect amyloidosis based on your symptoms, and will perform a physical exam, including blood or urine tests. The only way your doctor can definitively diagnose amyloidosis is using a needle to remove a small amount of tissue to test for amyloid (called a biopsy). With hereditary amyloidosis, DNA tests may reveal the genetic change that caused the condition. Special x-ray studies of tissue samples may show the structure of amyloid deposits. Depending on the signs and symptoms, your health care provider may use other tests to learn more about your condition, such as which organs are affected and whether your condition is getting worse.

Treatment Options

There is no cure for amyloidosis. Treatment focuses on lessening symptoms and reducing production of amyloid through diet and medications.

Prevention

Those who have hereditary amyloidosis should consider going to genetic counseling to learn about the risks of passing the condition to their children.

Treatment Plan

Treatment involves decreasing the proteins can make up amyloid. Doctors may use chemotherapy to treat AL. Depending on which organs are affected, your health care provider may ask you to follow a special diet (a low-sodium diet, for example, may help control fluid retention if your heart or kidneys are affected). There is no cure for AA, but medication can improve survival. The underlying condition must be treated. A liver transplant may be necessary for hereditary amyloidosis.

Drug Therapies

Doctors use combination of prednisone (a corticosteroid) and melphalan (Alkeran, also used to treat some kinds of cancer) to treat AL. Stem cell transplants are also a treatment for AL.

To help manage symptoms, your health care provider may suggest:

• Diuretics to relieve swelling caused by fluid retention
• Anti-arrhythmics to control heart rhythm
• Metoclopramide to help empty food from the stomach
• Antibiotics to control bacteria that may cause diarrhea or prevent the body from absorbing nutrients
• Anti-inflammatory/immune suppressive therapy to reduce amyloid precursor load

Surgical and Other Procedures

Depending on which parts of the body are affected, if you have amyloidosis you may need one of the following procedures:

• Dialysis, if the kidneys are failing
• Kidney, liver, heart, or bone marrow transplant
• Spleen removal
• Pacemaker implantation to control heart rhythm

Complementary and Alternative Therapies

Dietary choices, supplements, and herbs that reduce inflammation may help prevent amyloidosis. Damage from oxidation may play a role in the development of amyloidosis (see What Causes It? section), so you may want to add antioxidants to your diet to help slow the disease. Not all antioxidants are compatible with certain medications. Amyloidosis should never be treated with complementary and alternative therapies alone. Work with a knowledgeable provider and inform all of your health care providers about any medications, herbs, or supplements you are taking.

Nutrition and Supplements

Studies suggest that the following dietary choices may help prevent amyloidosis in people who are at high risk, or help slow the disease once it has developed:

• Limit the amount of meat you consume. Researchers suspect that a substance called amyloid enhancing factor (AEF), sometimes found in diseased animal foods, may increase the risk of amyloidosis in people who eat these foods. AEF has been shown to accelerate the growth of amyloid deposits in mice.
• Fish oil supplements (1,000 mg capsule, 1 to 2 times per day), which are high in omega-3 fatty acids, appear to help prevent amyloidosis in mice and may help reduce inflammation in chronic inflammatory conditions, such as rheumatoid arthritis. Fish oil can have a blood-thinning effect. If you are taking blood-thinning medications, such as warfarin (Coumadin) and aspirin, speak to your doctor before taking fish oil.
• Vitamin C (1 to 2 g per day). One animal study suggested that high doses of vitamin C may help the body break down amyloid and prevent amyloidosis from worsening, but there is no evidence this works in humans.

Additional supplements may include:

• DMSO (dimethyl sulfoxide, 7 to 15 g per day orally, and 50 to 100% solution applied to skin topically 2 times per week), an organic liquid that is used as an industrial solvent, has shown mixed results in scientific studies. Never take DMSO without your doctor's supervision.
• Bromelain (250 to 500 mg, 3 times per day), an enzyme derived from pineapple, fights inflammation and may help break down amyloid deposits in kidney tissue, though evidence is slight. Bromelain is often combined with turmeric, which strengthens its effects. Bromelain can interact with certain medications including some antibiotics. Bromelain has a blood-thinning effect, and may increase the effect of blood-thinning medications, such as warfarin (Coumadin) and aspirin.
• Resveratrol, an antioxidant found in grape skins, grape juice, and wine (especially red wine), may help reduce free radicals that encourage amyloid production. There is no established dosage, so talk to your doctor. There is some concern that resveratrol may have estrogen-like effects, so people with a history of hormone-related conditions should consult their doctors. Don't take resveratrol if you take blood-thinning medication or have high blood pressure or heart failure.
• Glutathione is an antioxidant produced by the body. Low levels may be associated with higher levels of beta2-microglobulin in people on dialysis with or without amyloidosis. This suggests there may be a link between glutathione levels in the blood and development or worsening of beta2-microglobulin amyloidosis. Studies have not evaluated supplementation with glutathione for amyloidosis. Some doctors may recommend 500 mg, 2 - 3 times a day, for people on dialysis to prevent the disease. Several glutathione supplements are available, but some are of questionable quality. Consult a trained, naturally-oriented doctor to make sure you get a high-quality supplement.
• Quercetin (500 mg, 2 times per day) is an antioxidant with anti-inflammatory properties. It has not been studied for amyloidosis. Quercetin can interact with certain medications and at high doses, there have been isolated reports of kidney damage. Speak with your physician.

To help prevent inflammation in general:

• Avoid processed foods, caffeine, food additives, dairy products, and refined sugars.
• Eat more whole grains, fresh fruits and vegetables, nuts, seeds, and cold-water fish.

Herbs

Flavonoids are plant compounds that fight damage from stress, oxidation, and inflammation. They may be useful as a supportive therapy to standard medical care in treating amyloidosis:

• Pycnogenol ( Pinus pinaster , 200 mg per day), which comes from the bark of French maritime pine, is rich in flavonoids. One laboratory study suggested that Pycnogenol protected cells of cattle from free radical damage due to amyloid deposits. Pycnogenol may stimulate the immune system, so talk to your doctor before taking Pycnogenol if you have an autoimmune condition. Pycnogenol may also lower blood sugar, as well as increase the risk of bleeding in people with bleeding disorders, and/or those taking blood-thinning medications, such as warfarin (Coumadin).
• Gingko (Gingko biloba) extract also contains flavonoids. It has been suggested as a treatment for Alzheimer's disease. Given the link between Alzheimer's and amyloid deposits, gingko may help treat amyloidosis as well, especially because it is also an antioxidant. Gingko may not be appropriate for people with certain conditions, such as diabetes, seizures, bleeding disorders, or those actively trying to get pregnant. Gingko can have a blood-thinning effect, and may increase the effect of blood-thinning medications, such as warfarin (Coumadin) and aspirin.

Prognosis/Possible Complications

Previously, AL was thought to be untreatable and deadly. With current therapy, many patients survive more than 5 years. About 20% survive 5 years or longer. With AA, most people survive 5 - 10 years after their condition surfaces. Survival depends on how well the underlying condition is treated. In hereditary amyloidosis, the outlook varies depending on the type of gene mutation and when the condition is diagnosed. Some people survive as long as 15 years after the disease develops.

Following Up

After diagnosis, your doctor may perform tests on a regular basis to check levels of protein-related substances, the size and placement of amyloid deposits, the development of the disease, and the effects of treatment.

Supporting Research

Bastianetto S, Ramassamy C, Doré S, Christen Y, Poirier J, Quirion R. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci. 2000;12(6):1882-1890.

Beers MH, Porter R, eds. The Merck Manual of Diagnosis and Therapy . 18th ed. Whitehouse Station, NJ: Merck Research Laboratories; 2006:1310-1312.

Buxbaum J. Treatment and prevention of the amyloidoses: can the lessons learned by applied to sporadic inclusion-body myositis? Neurology. 2006;66(2 Suppl 1):S110-S113.

Falk RH, Skinner M. The systemic amyloidoses: an overview. Adv Intern Med . 2000;45:107-137.

Ferri FF. Amyloidosis . Ferri's Clinical Advisor 2015. Philadelphia, PA: Elsevier Mosby; 2015:86.e2-86.e5.

Gertz MA. Amyloidosis. In: Goldman L, Schafer AI, eds. Goldman's Cecil Medicine, 24th ed. Philadelphia, PA: Elsevier Saunders; 2012:1243-1246.

Goldman L. Inherited and metabolic hepatic disorders. Goldman's Cecil Medicine. 23rd ed. Philadelphia, PA: Elsevier Saunders; 2008:1436-1437;2083-2087.

Hazenberg B. Amyloidosis: a clinical overview. Rheumatic Diseases Clinics of North America . 2013:39(2):323-345.

Hoffman R, Benz EJ, Silberstein LE, Heslop HE, Weitz JI, Anastasi J, eds.: Hematology: Basic Principles and Practice, 6th ed. Philadelphia, PA: Elsevier Saunders; 2013.

Kholova I, Kautzner J. Current treatment in cardiac amyloidosis. Curr Treat Options Cardiovasc Med. 2006;8(6):468-473.

Lebrazi H, Hachulla E, Saile R. Treatments for amyloidosis beyond symptomatic care [in French]. Rev Med Interne. 2000;21(3):247-255.

Lim GP, Calon F, Morihara T, et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci . 2005 Mar 23;25(12):3032-3040.

Liu F, Lau BH, Peng Q, Shah V. Pycnogenol protects vascular endothelial cells from beta-amyloid-induced injury. Biol Pharm Bull. 2000;23(6):735-737.

Maneti L, Tansinda P, Vaglio A. Eprodisate in amyloid A amyloidosis: a novel therapeutic approach? Expert Opin Pharmacother. 2008;9(12):2175-2180.

Morena M, Cristol J, Canaud B. Why hemodialysis patients are in a prooxidant state? What could be done to correct the pro/antioxidant imbalance. Blood Purif. 2000;18(3):191-199.

Okuda Y, Yamada T, Matsuura M, Takasugi K, Goto M. Ageing: a risk factor for amyloid A amyloidosis in rheumatoid arthritis. Amyloid. 2011:18(3):108-111.

Pettersson T, Konttinen YT, Maury CP. Treatment strategies for amyloid A amyloidosis. Expert Opin Pharmacother. 2008;9(12):2117-2128.

Seldin DC, Skinner M. Amyloidosis. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, eds. Kelley's Textbook of Rheumatology, 9th ed . Philadelphia, PA: Elsevier Saunders; 2008:1889-1897.

Sezer O, Eucker J, Schmid P, Possinger K. New therapeutic approaches in primary systemic AL amyloidosis. Ann Hematol. 2000;79(1):1-6.

Sideras K, Gertz MA. Amyloidosis. Adv Clin Chem. 2009;47:1-44.

Stankovic K, Grateau G. Amyloidosis AA. Nephrol Ther. 2008;4(4):281-287.

Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu ASL, Brenner BM, eds. Brenner and Rector's The Kidney, 9th ed. Philadelphia, PA: Elsevier Saunders; 2011.

Unverdi S, Inal S, Ceri M, et al. Is colchicine therapy effective in all patients with secondary amyloidosis? Ren Fail. 2013;35(8):1071-1074.

Vasala M, Immonen K, Kautiainen H, Hakala M. More evidence of declining incidence of amyloidosis associated with inflammatory rheumatic diseases. Scan J Rheumatol. 2010: 39(6):461-465.

Wettstein A. Cholinesterase inhibitors and ginkgo extracts -- are they comparable in the treatment of dementia? Phytomedicine . 2000;6(6):393-401.

Zubkov A, Rabinstein A, Dispenzieri A, Wijdicks E. Primary systemic amyloidosis with ischemic stroke as presenting complication. Neurology . 2007;69(11):1136-41.